Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Daubeuf, M. Hachet-Haas, P. Gizzi, V. Gasparik, D. Bonnet, V. Utard, M. Hibert, N. Frossard, J. L. Galzi (Illkirch, France). An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in the mouse. Eur Respir J 2013; 42: Suppl. 57, 1760

Member's Comments

No comment yet.

Related content which might interest you: Activation of the β-catenin pathway by Wnt-1 treatment suppress inflammation in the mouse model of allergic airway disease Source: International Congress 2015 – Advances in asthma and allergy in animal models Year: 2015 Effect of roflumilast on airway remodeling in a murine model of chronic asthma Source: International Congress 2015 – New models for treating airway diseases Year: 2015 The effect of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild to moderate asthma Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 IL-37 requires IL18Rα and SIGIRR to diminish experimental allergic airway inflammation in mice Source: International Congress 2015 – Animal studies of asthma and other inflammatory conditions Year: 2015 GARP reduces inflammation in a humanized mouse model of allergic airway disease Source: International Congress 2015 – Advances in asthma and allergy in animal models Year: 2015 Combining an epithelial repair factor and anti-fibrotic with a corticosteroid offers optimal treatment for the pathogenesis of allergic airways disease Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016 The effects of clinically relevant reference agents in a mouse model of severe asthma Source: International Congress 2015 – Advances in the future treatment of severe asthma Year: 2015 Neutraligands of CXCL12: Anti-inflammatory activity in an allergic model of asthma Source: Annual Congress 2011 - Models of disease and drug actions Year: 2011 A novel inhaled PI3Kδ inhibitor, LAS194223 reduces allergen-induced airway inflammation in rat Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 Resveratrol upregalates PTEN and inhibits MUC5AC expression in ovalbumin (OVA)-induced asthma model mice Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016 Dose-dependent differential effects of thrombin in allergic bronchial asthma Source: Annual Congress 2013 –Murine models of lung immunology Year: 2013 IL-13-induced cytokine release and hyperresponsiveness in precision cut lung slices of different species – Characterization of a model potentially suitable for translational research of asthma cellular events Source: Annual Congress 2013 –Origins and diagnosis of asthma Year: 2013 Bronchodilator effect of a novel inhaled dual PDE3/4 inhibitor, RPL554, in mild allergic asthma & rhinitis Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Treatment with Syk inhibitors after establishment of disease phenotype in a chronic HDM model of allergic airways inflammation abolishes AHR and attenuates inflammatory mediator expression Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 Lung specific induction of Wnt-1 has a prophylactic and therapeutic effect on the development of an allergic airway disease Source: Annual Congress 2013 –Murine models of lung immunology Year: 2013 The effect of anti-IL-33 antibody and soluble ST2 in a murine model of allergic asthma Source: Annual Congress 2013 –Murine models of lung immunology Year: 2013 IL33 and TSLP involvements in influenza-induced exacerbation in a murine model of chronic asthma Source: International Congress 2015 – Advances in asthma and allergy in animal models Year: 2015 The anti-inflammatory effects of PF03715455 and roflumilast on both cellular and tissue inflammation in a mouse model of COPD Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 IL-25 induces airways angiogenesis and expression of multiple angiogenic factors in a murine asthma model Source: International Congress 2015 – Asthma and lung immunology Year: 2015 Preventative administration of IL-27 improves airway inflammation of ovalbumin –induced asthma mice model via both STAT1 and GADD45γ/p38MAPK pathways Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016